Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399058 | 1.00 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL17310444 | 0.88 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL17310443 | 0.88 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL17310442 | 0.88 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL15073250 | 0.86 | NR1H2 (0.45) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL15147124 | 0.86 | NR1H2 (0.45) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL2738098 | 0.86 | NR1H2 (0.45) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL219779 | 0.86 | NR1H2 (0.45) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL2934516 | 0.86 | NR1H2 (0.45) | MEN1ALDH1A1MAPTKMT2ARECQL | |
| SCHEMBL13438546 | 0.86 | NR1H2 (0.45) | MEN1ALDH1A1MAPTKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | MEN1 4441/4885ALDH1A1 3655/4885MAPT 90/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | MEN1 4665/4885ALDH1A1 3623/4885MAPT 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.